Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1994 Nov 22;91(24):11762–11766. doi: 10.1073/pnas.91.24.11762

Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides.

N M Dean 1, R McKay 1
PMCID: PMC45312  PMID: 7972137

Abstract

A 20-mer phosphorothioate oligodeoxynucleotide designed to hybridize to the AUG translation initiation codon of mRNA encoding murine protein kinase C-alpha (PKC-alpha) inhibits the expression of PKC-alpha both in vitro and in vivo. In mouse C127 mammary epithelial cells, the reduction in PKC-alpha mRNA expression was both dose and time dependent. The oligodeoxynucleotide exhibited an IC50 value of 100-200 nM and reduced PKC-alpha mRNA expression for up to 48 hr. This reduction was specific for PKC-alpha versus other PKC isozymes (delta, epsilon, and zeta) and completely dependent upon oligodeoxynucleotide sequence. When administered intraperitoneally in mice, the same oligodeoxynucleotide caused a dose-dependent, oligodeoxynucleotide sequence-dependent reduction of PKC-alpha mRNA in liver, with an IC50 value of 30-50 mg/kg of body weight. Inhibition of expression was 64 +/- 11% after a single 50-mg/kg dose. The expression of PKC-delta, epsilon, and zeta mRNA was unaffected by this treatment. The oligodeoxynucleotide activity in vivo did not require the presence of cationic liposomes or any other delivery systems, although in vitro, the oligodeoxynucleotide required cationic liposomes for inhibition of PKC-alpha expression. This study demonstrates the utility of phosphorothioate oligodeoxynucleotides as specific inhibitors of gene expression in vivo after systemic administration.

Full text

PDF
11762

Images in this article

11763Image
on p.11763
11764Image
on p.11764
11765Image
on p.11765

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abeliovich A., Chen C., Goda Y., Silva A. J., Stevens C. F., Tonegawa S. Modified hippocampal long-term potentiation in PKC gamma-mutant mice. Cell. 1993 Dec 31;75(7):1253–1262. doi: 10.1016/0092-8674(93)90613-u. [DOI] [PubMed] [Google Scholar]
  2. Abeliovich A., Paylor R., Chen C., Kim J. J., Wehner J. M., Tonegawa S. PKC gamma mutant mice exhibit mild deficits in spatial and contextual learning. Cell. 1993 Dec 31;75(7):1263–1271. doi: 10.1016/0092-8674(93)90614-v. [DOI] [PubMed] [Google Scholar]
  3. Agrawal S., Temsamani J., Tang J. Y. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A. 1991 Sep 1;88(17):7595–7599. doi: 10.1073/pnas.88.17.7595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ahmad S., Glazer R. I. Expression of the antisense cDNA for protein kinase C alpha attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol Pharmacol. 1993 Jun;43(6):858–862. [PubMed] [Google Scholar]
  5. Akhtar S., Kole R., Juliano R. L. Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera. Life Sci. 1991;49(24):1793–1801. doi: 10.1016/0024-3205(91)90480-y. [DOI] [PubMed] [Google Scholar]
  6. Azad R. F., Driver V. B., Tanaka K., Crooke R. M., Anderson K. P. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob Agents Chemother. 1993 Sep;37(9):1945–1954. doi: 10.1128/aac.37.9.1945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ballester R., Rosen O. M. Fate of immunoprecipitable protein kinase C in GH3 cells treated with phorbol 12-myristate 13-acetate. J Biol Chem. 1985 Dec 5;260(28):15194–15199. [PubMed] [Google Scholar]
  8. Bednarczuk T. A., Wiggins R. C., Konat G. W. Generation of high efficiency, single-stranded DNA hybridization probes by PCR. Biotechniques. 1991 Apr;10(4):478–478. [PubMed] [Google Scholar]
  9. Bennett C. F., Chiang M. Y., Chan H., Shoemaker J. E., Mirabelli C. K. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol. 1992 Jun;41(6):1023–1033. [PubMed] [Google Scholar]
  10. Bennett C. F., Condon T. P., Grimm S., Chan H., Chiang M. Y. Inhibition of endothelial cell adhesion molecule expression with antisense oligonucleotides. J Immunol. 1994 Apr 1;152(7):3530–3540. [PubMed] [Google Scholar]
  11. Borner C., Eppenberger U., Wyss R., Fabbro D. Continuous synthesis of two protein-kinase-C-related proteins after down-regulation by phorbol esters. Proc Natl Acad Sci U S A. 1988 Apr;85(7):2110–2114. doi: 10.1073/pnas.85.7.2110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Chiang M. Y., Chan H., Zounes M. A., Freier S. M., Lima W. F., Bennett C. F. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem. 1991 Sep 25;266(27):18162–18171. [PubMed] [Google Scholar]
  13. Cossum P. A., Sasmor H., Dellinger D., Truong L., Cummins L., Owens S. R., Markham P. M., Shea J. P., Crooke S. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther. 1993 Dec;267(3):1181–1190. [PubMed] [Google Scholar]
  14. Cossum P. A., Truong L., Owens S. R., Markham P. M., Shea J. P., Crooke S. T. Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J Pharmacol Exp Ther. 1994 Apr;269(1):89–94. [PubMed] [Google Scholar]
  15. Cowsert L. M., Fox M. C., Zon G., Mirabelli C. K. In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: potential treatment for genital warts. Antimicrob Agents Chemother. 1993 Feb;37(2):171–177. doi: 10.1128/aac.37.2.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Crooke R. M. In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anticancer Drug Des. 1991 Dec;6(6):609–646. [PubMed] [Google Scholar]
  17. Crooke S. T. Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol. 1992;32:329–376. doi: 10.1146/annurev.pa.32.040192.001553. [DOI] [PubMed] [Google Scholar]
  18. Dean N. M., McKay R., Condon T. P., Bennett C. F. Inhibition of protein kinase C-alpha expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem. 1994 Jun 10;269(23):16416–16424. [PubMed] [Google Scholar]
  19. Gao W. Y., Storm C., Egan W., Cheng Y. C. Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells. Mol Pharmacol. 1993 Jan;43(1):45–50. [PubMed] [Google Scholar]
  20. Gescher A., Dale I. L. Protein kinase C--a novel target for rational anti-cancer drug design? Anticancer Drug Des. 1989 Aug;4(2):93–105. [PubMed] [Google Scholar]
  21. Godson C., Bell K. S., Insel P. A. Inhibition of expression of protein kinase C alpha by antisense cDNA inhibits phorbol ester-mediated arachidonate release. J Biol Chem. 1993 Jun 5;268(16):11946–11950. [PubMed] [Google Scholar]
  22. Higgins K. A., Perez J. R., Coleman T. A., Dorshkind K., McComas W. A., Sarmiento U. M., Rosen C. A., Narayanan R. Antisense inhibition of the p65 subunit of NF-kappa B blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9901–9905. doi: 10.1073/pnas.90.21.9901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hoke G. D., Draper K., Freier S. M., Gonzalez C., Driver V. B., Zounes M. C., Ecker D. J. Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex virus infection. Nucleic Acids Res. 1991 Oct 25;19(20):5743–5748. doi: 10.1093/nar/19.20.5743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Inoue H., Hayase Y., Iwai S., Ohtsuka E. Sequence-dependent hydrolysis of RNA using modified oligonucleotide splints and RNase H. FEBS Lett. 1987 May 11;215(2):327–330. doi: 10.1016/0014-5793(87)80171-0. [DOI] [PubMed] [Google Scholar]
  25. Kitajima I., Shinohara T., Bilakovics J., Brown D. A., Xu X., Nerenberg M. Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-kappa B. Science. 1992 Dec 11;258(5089):1792–1795. doi: 10.1126/science.1299224. [DOI] [PubMed] [Google Scholar]
  26. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  27. Monia B. P., Johnston J. F., Ecker D. J., Zounes M. A., Lima W. F., Freier S. M. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J Biol Chem. 1992 Oct 5;267(28):19954–19962. [PubMed] [Google Scholar]
  28. Morishita R., Gibbons G. H., Ellison K. E., Nakajima M., Zhang L., Kaneda Y., Ogihara T., Dzau V. J. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8474–8478. doi: 10.1073/pnas.90.18.8474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 1992 Oct 23;258(5082):607–614. doi: 10.1126/science.1411571. [DOI] [PubMed] [Google Scholar]
  30. Ratajczak M. Z., Kant J. A., Luger S. M., Hijiya N., Zhang J., Zon G., Gewirtz A. M. In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11823–11827. doi: 10.1073/pnas.89.24.11823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Rose-John S., Dietrich A., Marks F. Molecular cloning of mouse protein kinase C (PKC) cDNA from Swiss 3T3 fibroblasts. Gene. 1988 Dec 30;74(2):465–471. doi: 10.1016/0378-1119(88)90179-5. [DOI] [PubMed] [Google Scholar]
  32. Schwartz G. K., Jiang J., Kelsen D., Albino A. P. Protein kinase C: a novel target for inhibiting gastric cancer cell invasion. J Natl Cancer Inst. 1993 Mar 3;85(5):402–407. doi: 10.1093/jnci/85.5.402. [DOI] [PubMed] [Google Scholar]
  33. Simons M., Edelman E. R., DeKeyser J. L., Langer R., Rosenberg R. D. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature. 1992 Sep 3;359(6390):67–70. doi: 10.1038/359067a0. [DOI] [PubMed] [Google Scholar]
  34. Stein C. A., Cheng Y. C. Antisense oligonucleotides as therapeutic agents--is the bullet really magical? Science. 1993 Aug 20;261(5124):1004–1012. doi: 10.1126/science.8351515. [DOI] [PubMed] [Google Scholar]
  35. Temsamani J., Tang J. Y., Padmapriya A., Kubert M., Agrawal S. Pharmacokinetics, biodistribution, and stability of capped oligodeoxynucleotide phosphorothioates in mice. Antisense Res Dev. 1993 Fall;3(3):277–284. doi: 10.1089/ard.1993.3.277. [DOI] [PubMed] [Google Scholar]
  36. Ulmer J. B., Donnelly J. J., Parker S. E., Rhodes G. H., Felgner P. L., Dwarki V. J., Gromkowski S. H., Deck R. R., DeWitt C. M., Friedman A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993 Mar 19;259(5102):1745–1749. doi: 10.1126/science.8456302. [DOI] [PubMed] [Google Scholar]
  37. Wagner R. W., Matteucci M. D., Lewis J. G., Gutierrez A. J., Moulds C., Froehler B. C. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science. 1993 Jun 4;260(5113):1510–1513. doi: 10.1126/science.7684856. [DOI] [PubMed] [Google Scholar]
  38. Wahlestedt C., Pich E. M., Koob G. F., Yee F., Heilig M. Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science. 1993 Jan 22;259(5094):528–531. doi: 10.1126/science.8380941. [DOI] [PubMed] [Google Scholar]
  39. Wilkinson S. E., Hallam T. J. Protein kinase C: is its pivotal role in cellular activation over-stated? Trends Pharmacol Sci. 1994 Feb;15(2):53–57. doi: 10.1016/0165-6147(94)90110-4. [DOI] [PubMed] [Google Scholar]
  40. Young S., Parker P. J., Ullrich A., Stabel S. Down-regulation of protein kinase C is due to an increased rate of degradation. Biochem J. 1987 Jun 15;244(3):775–779. doi: 10.1042/bj2440775. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES